Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction

Abstract The elexacaftor/tezacaftor/ivacaftor (ETI) combination for cystic fibrosis transmembrane regulator modulators is a safe and effective treatment in both adults and children who are homozygous or compound heterozygous for the F508del variant. However, few cases involving a significant reducti...

Full description

Saved in:
Bibliographic Details
Main Authors: Alice Castaldo, Chiara Cimbalo, Cristina Fevola, Vincenzo Carnovale, Paola Iacotucci, Valeria Raia, Vito Terlizzi, Monica Gelzo, Angela Sepe, Antonella Tosco
Format: Artigo
Language:Inglês
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Cystic fibrosis
Elexacaftor/tezacaftor/ivacaftor
Platelets
Inflammation
Online Access:https://doi.org/10.1038/s41598-025-12333-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items